| Style | Citing Format |
|---|---|
| MLA | Esmaeili Z, et al.. "Nanotechnology-Driven Egcg: Bridging Antioxidant and Therapeutic Roles in Metabolic and Cancer Pathways." Nanomedicine, vol. 20, no. 6, 2025, pp. 621-636. |
| APA | Esmaeili Z, Shavali Gilani P, Khosravani M, Motamedi M, Maleknejad S, Adabi M, Sadighara P (2025). Nanotechnology-Driven Egcg: Bridging Antioxidant and Therapeutic Roles in Metabolic and Cancer Pathways. Nanomedicine, 20(6), 621-636. |
| Chicago | Esmaeili Z, Shavali Gilani P, Khosravani M, Motamedi M, Maleknejad S, Adabi M, Sadighara P. "Nanotechnology-Driven Egcg: Bridging Antioxidant and Therapeutic Roles in Metabolic and Cancer Pathways." Nanomedicine 20, no. 6 (2025): 621-636. |
| Harvard | Esmaeili Z et al. (2025) 'Nanotechnology-Driven Egcg: Bridging Antioxidant and Therapeutic Roles in Metabolic and Cancer Pathways', Nanomedicine, 20(6), pp. 621-636. |
| Vancouver | Esmaeili Z, Shavali Gilani P, Khosravani M, Motamedi M, Maleknejad S, Adabi M, et al.. Nanotechnology-Driven Egcg: Bridging Antioxidant and Therapeutic Roles in Metabolic and Cancer Pathways. Nanomedicine. 2025;20(6):621-636. |
| BibTex | @article{ author = {Esmaeili Z and Shavali Gilani P and Khosravani M and Motamedi M and Maleknejad S and Adabi M and Sadighara P}, title = {Nanotechnology-Driven Egcg: Bridging Antioxidant and Therapeutic Roles in Metabolic and Cancer Pathways}, journal = {Nanomedicine}, volume = {20}, number = {6}, pages = {621-636}, year = {2025} } |
| RIS | TY - JOUR AU - Esmaeili Z AU - Shavali Gilani P AU - Khosravani M AU - Motamedi M AU - Maleknejad S AU - Adabi M AU - Sadighara P TI - Nanotechnology-Driven Egcg: Bridging Antioxidant and Therapeutic Roles in Metabolic and Cancer Pathways JO - Nanomedicine VL - 20 IS - 6 SP - 621 EP - 636 PY - 2025 ER - |